Overcoming Obstacles to Health Equity in Breast Cancer Prevention and Control
The current scientific evidence may not be generalizable to underrepresented groups.
Breast Cancer
BREAST CANCER ADVISOR
FEATURED CONTENT
-
-
On-Treatment Ki-67: A Promising Prognostic Marker for Early Breast Cancer Management
Dr Alan Lyss reviews results from the high-risk cohort of the WSG-ADAPT HR+/HER2- trial. -
ASCO and Friends: Cancer Patients Should Be Included in COVID-19 Vaccine Trials
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials. -
Closing the Gap Between Cancer Patients and Researchers: A Patient Advocate’s Perspective on GRASP
Patient advocate Marlena Murphy provides a patient’s perspective on GRASP. -
The Past, Present, and Future of GRASP: Connecting Cancer Researchers, Clinicians, and Patient Advocates
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
VIDEO SERIES
The Phase 3 PlanB Trial
Continue to Work?
2016 SABCS: Clinical Insights Telli
2016 SABCS: Clinical Insights Oregan
HER2-positive Metastatic and TNBC
Frontline Treatments
Treatment-related Neuropathy
ER-positive, HER2-negative
Emerging Medicines
Triple-negative Breast Cancer
Insights from the Lab and Clinic
Trastuzumab Resistance
Biologic Role of HER2
Strategies in Management
BREAST CANCER NEWS
Keytruda Combo Approved for High-Risk Early-Stage Triple-Negative Breast Cancer
Extended Bisphosphonate Treatment Does Not Improve Survival in High-Risk Early Breast Cancer
Factors ID’d for Radiologist Performance in Screening Mammography
Disparities in Breast Cancer Survival Persist for Black Women
Trastuzumab Emtansine in Stage I HER2+ Breast Cancer
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Breast Cancer
Loading... 
Loading...